This is not a sale, it's better... MarketersMEDIA Year End Sale 2019 is now Live! Shop Now
MarketersMEDIA / Newsroom / Intravenous Immunoglobulin market Size, Share Poised to Touch USD 16,882.15 Million by 2026

Intravenous Immunoglobulin market Size, Share Poised to Touch USD 16,882.15 Million by 2026

Share This Press Release

Market Study Report Provides A Detailed Overview Of Intravenous Immunoglobulin Market With Respect To The Pivotal Drivers Influencing The Revenue Graph Of This Business Sphere.

— The Global Intravenous Immunoglobulin Market Size is anticipated to reach over USD 16,882.15 Million by 2026, according to a new research

Request a sample of this premium report titled at: https://www.marketstudyreport.com/request-a-sample/1695093?utm_source=marketersmedia.com&utm_medium=ADS

According to the Centers for Disease Control and Prevention (CDC) in 2012, the global occurrence rate of hypogammaglobulinemia was around 2 per 100,000 populations moreover, the number of people suffering this type of disease are estimated to increase during the forecast period. Growing occurrence of immunodeficiency disorders associated with the high implementation of IVIG therapies is expected to drive the segment growth significantly.

Immunoglobulins (IGs) are glycoproteins that are formed in the blood plasma in response to the antigens (Ag), which are considered as a foreign material to the host system. IGs are highly composite objects and precise in their nature. They are achieved from blood by fractionation procedure and filtered fo non-therapeutic as well as therapeutic applications. In therapeutics, they are administered intravenously for the treatment of several immunodeficiency.

The global Intravenous Immunoglobulin Market majorly is driven by rising elderly population, increasing occurrence of immunodeficiency disorders, growing implementation of IVIG procedures and increasing usage of off-label indications. Increasing number of patients with immunodeficiency disease is the primary reason for the expansion of IVIG procedures. According to the World Health Organization (WHO), there are approximately 50 diverse Primary Immune Deficiency (PID) such as X-lined hypo-gamma-globulinemia, specific antibody deficiency and others. Moreover, according to the U.S. National Library of Medicine and National Institute of Health, around 6 million patients are suffering from PID globally. Rising occurrences of these immune diseases is anticipated to bolster the demand for intravenous immunoglobulin treatments during the forecast period.

The demand for IVIG treatments for the primary and acquired immunodeficiency disorder is growing as it is the only available as well as most effective treatment option. Moreover, inactive lifestyle behaviors, including intake of saturated fats, sugars and salts, less physical actions, and high alcohol intake have led to the surge in the occurrence of such diseases. Increasing occurrence of such lifestyle related disease including antibody deficiency disorders and obesity are the factors anticipated to drive the global intravenous immunoglobulin market growth.

Request a discount on standard prices of this premium report titled at: https://www.marketstudyreport.com/check-for-discount/1695093?utm_source=marketersmedia.com&utm_medium=ADS

The global Intravenous Immunoglobulin Market is segmented on the basis of Application and geography. On the basis of application, the global Intravenous Immunoglobulin Market is categorized into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Multifocal motor neuropathy, Myasthenia Gravis, Chronic Lymphocytic Leukemia, Kawasaki disease, Guillain-Barre syndrome, and Idiopathic Thrombocytopenic Purpura (ITP). In 2017, Hypogammaglobulinemia is estimated to dominate the application segment. The dominancy is attributed to the growing global occurrences of primary immunodeficiency diseases (PID). It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).

Some major key players in global Intravenous Immunoglobulin Market include Baxter International Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare among others.

Table of Contents:

1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Intravenous Immunoglobulin Market Insights
4. Intravenous Immunoglobulin Market Size and Forecast by Application
5. Intravenous Immunoglobulin Market Size and Forecast by Regions
6. Company Profiles

Questions? Get them answered via https://www.marketstudyreport.com/enquiry-before-buying/1695093?utm_source=marketersmedia.com&utm_medium=ADS before taking a buying decision on this premium report titled Global Intravenous Immunoglobulin Market

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Market Study Report
Address: 4 North Main Street, Selbyville, Delaware 19975 USA
Phone: 1-302-273-0910
Website: https://www.marketstudyreport.com

Source URL: https://marketersmedia.com/intravenous-immunoglobulin-market-size-share-poised-to-touch-usd-1688215-million-by-2026/88933829

Source: MarketersMedia

Release ID: 88933829

Latest Releases

Subscribe and Receive exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2019 MarketersMEDIA – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).